Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Opus Genetics (Nasdaq: IRD) announced on Dec 2, 2025 that its Compensation Committee approved inducement equity awards under the company’s 2021 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Opus Genetics (Nasdaq: IRD) announced on Dec 2, 2025 that its Compensation Committee approved inducement equity awards under the company’s 2021 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The awards were granted to two new non-executive employees as options to purchase an aggregate of 124,000 shares of common stock. The options have an exercise price equal to the fair market value on the grant date and vest over four years: 25% at one year and the remaining 75% in quarterly installments, subject to acceleration or forfeiture as set in each award agreement.
Details
News Market Reaction – IRD
On Dec 3, the first trading day after this news, IRD closed 5.03% above the previous close.
Data tracked by StockTitan Argus for the Dec 3 session.
Key Figures
- Inducement option grant
- 124,000 shares
- Aggregate options granted to two non-executive new hires
- New employees
- 2 employees
- Non-executive hires receiving inducement equity awards
- Vesting period
- 4 years
- Option awards vest over four-year schedule
- Cliff vesting
- 25% at 1 year
- Initial vesting on first anniversary of grant date
- Remainder vesting
- 75% quarterly
- Remaining options vest in quarterly installments thereafter
Historical Context
-
IDMC gave positive recommendation to continue BEST1 Phase 1/2 trial.
-
Nasdaq Rule 5635(c)(4) inducement options for two new employees.
-
Management participation in two early December healthcare investor events.
-
First participant dosed in OPGx‑BEST1 Phase 1/2 trial for Best disease.
-
Q3 2025 results with RMAT meeting and LCA5/BEST1 program updates.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
RESEARCH TRIANGLE PARK, N.C., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders (the “Company”), today announced that the Compensation Committee of its Board of Directors approved equity awards under the Company’s 2021 Inducement Plan, as amended, as a material inducement to employment to two non-executive employees who were not previous employees or directors of the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4), which also requires a public announcement of any equity awards that are not made under a stockholder approved equity plan.
The equity awards for the two employees were granted in the form of options to purchase an aggregate of 124,000 shares of the Company’s common stock. The option awards have an exercise price equal to the fair market value of an underlying share of Company common stock as of the date of grant and vest over a period of four years, with
About Opus Genetics
Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs). The Company is developing durable, one-time treatments designed to address the underlying genetic causes of severe retinal disorders. The Company’s pipeline includes seven AAV-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, RDH12, and MERTK. Opus Genetics is also advancing Phentolamine Ophthalmic Solution
Contacts
Investors
Jenny Kobin
Remy Bernarda
IR Advisory Solutions
ir@opusgtx.com
Media
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.